Cocrystal Pharma (COCP) vs IGC Pharma (IGC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Cocrystal Pharma (COCP) has outperformed IGC Pharma (IGC) over the past year, gaining 5.6% versus a loss of 47.5%. Over five years, IGC leads with a -87.6% price change compared with -91.8% for COCP. IGC Pharma is the larger company by market cap ($19.6 million vs $18.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | COCP | IGC |
|---|---|---|
| Share price | $0.95 | $0.168 |
| Market cap | $18.30M | $19.60M |
| 1-day change | -2.05% | -8.70% |
| YTD return | -3.06% | -40.00% |
| 1-year return | +5.56% | -47.50% |
| 5-year return | -91.84% | -87.65% |
| EPS (TTM) | $-0.76 | $-0.07 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $1.27M |
| Revenue growth (YoY) | — | -5.50% |
| Net income (latest FY) | $-8.83M | $-7.12M |
| Gross margin | — | 48.70% |
| Operating margin | — | -585.84% |
| Net margin | — | -560.35% |
| 52-week high | $2.03 | $0.36 |
| 52-week low | $0.76 | $0.08 |
| Distance from 52-week high | -53.20% | -53.33% |
| Analyst consensus | none | none |
| Avg. price target upside | +847.37% | +3471.43% |
| Average volume | 40.65K | 615.25K |
| Shares outstanding | 19.26M | 116.69M |
| Employees | 10 | 70 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- COCP has outperformed IGC by 53.1 percentage points over the past year.
About Cocrystal Pharma
COCP stock →Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hepatitis C virus (HCV) infections.
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
About IGC Pharma
IGC stock →IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's.
Health Care · Biotechnology: Pharmaceutical Preparations · 70 employees
COCP vs IGC FAQ
Which is bigger, Cocrystal Pharma or IGC Pharma?
IGC Pharma (IGC) is larger, with a market capitalization of $19.60M compared with $18.30M for Cocrystal Pharma (COCP).
Which stock has performed better over the past year, COCP or IGC?
COCP returned +5.56% over the past 12 months, compared with -47.50% for IGC (price return, excluding dividends). Past performance does not predict future results.
Are Cocrystal Pharma and IGC Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.